Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
entacapone
Teva Pharma B.V.
N04BX02
entacapone
Anti-Parkinson drugs
Parkinson Disease
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Revision: 10
Authorised
2011-02-18
20 B. PACKAGE LEAFLET 21 PACKAGE LEAFLET: INFORMATION FOR THE USER ENTACAPONE TEVA 200 MG FILM-COATED TABLETS entacapone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Entacapone Teva is and what it is used for 2. What you need to know before you take Entacapone Teva 3. How to take Entacapone Teva 4. Possible side effects 5. How to store Entacapone Teva 6. Contents of the pack and other information 1. WHAT ENTACAPONE TEVA IS AND WHAT IT IS USED FOR Entacapone Teva tablets contain entacapone and are used together with levodopa to treat Parkinson’s disease. Entacapone Teva aids levodopa in relieving the symptoms of Parkinson's disease. Entacapone Teva has no effect on relieving the symptoms of Parkinson´s disease unless taken with levodopa. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTACAPONE TEVA DO NOT TAKE ENTACAPONE TEVA • if you are allergic to entacapone or any of the other ingredients of this medicine (listed in section 6); • if you have a tumour of the adrenal gland (known as pheochromocytoma; this may increase the risk of severe high blood pressure); • if you are taking certain antidepressants (ask your doctor or pharmacist whether your antidepressive medicine can be taken together with Entacapone Teva); • if you have liver disease; • if you have ever suffered from a rare reaction to antipsychotic medicines called neuroleptic malignant syndrome (NMS). See section 4 Possible side effects for the characteristics of NMS; • if you have ever suffered from a rare muscle disorder Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Entacapone Teva 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 200 mg entacapone. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light brown, biconvex, ellipse-shaped film-coated tablets with approximately 18 mm length and 10 mm width, embossed ‘E200’ on one side, plain on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson’s disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Entacapone should only be used in combination with levodopa/benserazide or levodopa/carbidopa. The prescribing information for these levodopa preparations is applicable to their concomitant use with entacapone. Posology One 200 mg tablet is taken with each levodopa/dopa decarboxylase inhibitor dose. The maximum recommended dose is 200 mg ten times daily, i.e. 2,000 mg of entacapone. Entacapone enhances the effects of levodopa. Hence, to reduce levodopa-related dopaminergic adverse reactions, e.g. dyskinesias, nausea, vomiting and hallucinations, it is often necessary to adjust levodopa dosage within the first days to first weeks after initiating entacapone treatment. The daily dose of levodopa should be reduced by about 10-30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. If entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations slightly (5-10%) more than from standard levodo Lesen Sie das vollständige Dokument